As filed with the Securities and Exchange Commission on March 30, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KemPharm, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
20-5894398 |
|
|
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
2500 Crosspark Road, Suite E126
Coralville, IA 52241
(Address of Principal Executive Offices) (Zip Code)
2014 Equity Incentive Plan
(Full Title of the Plan)
R. LaDuane Clifton, CPA
Chief Financial Officer, Secretary and Treasurer
KemPharm, Inc.
2500 Crosspark Road, Suite E126
Coralville, IA 52241
(319) 665-2575
(Name and Address of Agent for Service) (Telephone Number, Including Area Code, of Agent for Service)
Copies to:
|
Brent B. Siler Matthew P. Dubofsky Cooley LLP 380 Interlocken Crescent, Suite 900 Broomfield, CO 80021 (720) 566-4000 |
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ (Do not check if a smaller reporting company) Smaller reporting company ☒
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
CALCULATION OF REGISTRATION FEE
|
Title of Securities to be Registered |
Amount to be Registered (1) |
Proposed Maximum Offering Price Per Share (2) |
Proposed Maximum Aggregate Offering Price (2) |
Amount of Registration Fee |
|
Common Stock, par value $0.0001 per share |
586,297 shares |
$7.65 |
$4,485,172.05 |
$558.40 |
|
(1) |
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”) that become issuable under the 2014 Equity Incentive Plan (the “2014 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock. |
|
(2) |
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon the average high and low prices of the Registrant’s Common Stock as reported on the NASDAQ Global Market on March 29, 2018. The chart below details the calculations of the registration fee: |
|
Securities |
Number of Shares |
Offering Price Per Share (2) |
Aggregate Offering Price |
|
Additional shares reserved for future grant under the 2014 Plan |
586,297 |
$7.65 (2) |
$4,485,172.05 |
|
Proposed Maximum Aggregate Offering Price |
|
$4,485,172.05 |
|
|
Registration Fee |
$558.40 |
Explanatory Note
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 586,297 shares of the Registrant’s Common Stock to be issued pursuant to the Registrant’s 2014 Plan.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION
STATEMENT ON FORM S-8
The Registrant is hereby registering an additional 586,297 shares of the Registrant’s Common Stock to be issued pursuant to the Registrant’s 2014 Plan. The contents of the Registration Statement on Form S-8 (File No. 333-203703), as filed with the Securities and Exchange Commission (the “Commission”) on April 29, 2015, are incorporated herein by reference and made a part of this Registration Statement.
ITEM 8. EXHIBITS
|
(1) |
Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-36913), filed with the Commission on April 21, 2015, and incorporated by reference herein. |
|
(2) |
Previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36913), filed with the Commission on April 21, 2015, and incorporated by reference herein. |
|
(3) |
Previously filed as Exhibit 4.2 to Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-202660), filed with the Commission on April 9, 2015, and incorporated by reference herein. |
|
(4) |
Previously filed as Exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 (File No. 333-203703), filed with the Commission on April 29, 2015, and incorporated by reference herein. |
|
(5) |
Previously filed as Exhibit 10.15 to the Registrant’s Registration Statement on Form S-1 (File No. 333-202660), filed with the Commission on March 11, 2015, and incorporated by reference herein. |
|
(6) |
Previously filed as Exhibit 10.16 to the Registrant’s Registration Statement on Form S-1 (File No. 333-202660), filed with the Commission on March 11, 2015, and incorporated by reference herein. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Coralville, State of Iowa, on this 30th day of March, 2018.
| KemPharm, Inc. | ||
| By: | /s/ R. LaDuane Clifton | |
| R. LaDuane Clifton, CPA | ||
| Chief Financial Officer, Secretary and Treasurer | ||
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Travis C. Mickle, Ph.D. and R. LaDuane Clifton, CPA and each or any one of them, his lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||||
|
/s/ Travis C. Mickle |
||||||
|
Travis C. Mickle, Ph.D. |
President, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) |
March 30, 2018 |
||||
|
/s/ R. LaDuane Clifton |
||||||
|
R. LaDuane Clifton, CPA |
Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer) |
March 30, 2018 | ||||
|
/s/ Timothy J. Sangiovanni |
||||||
| Timothy J. Sangiovanni, CPA |
Vice President, Corporate Controller (Principal Accounting Officer) |
March 30, 2018 | ||||
|
/s/ Danny L. Thompson |
|
|||||
| Danny L. Thompson | Director | March 30, 2018 | ||||
|
/s/ Matthew R. Plooster |
||||||
|
Matthew R. Plooster |
Director |
March 30, 2018 | ||||
|
/s/ Richard W. Pascoe |
||||||
|
Richard W. Pascoe |
Director |
March 30, 2018 | ||||
|
/s/ Joseph B. Saluri |
||||||
|
Joseph B. Saluri |
Director |
March 30, 2018 | ||||
|
/s/ David S. Tierney |
||||||
|
David S. Tierney |
Director |
March 30, 2018 | ||||
6
Exhibit 5.1
Matthew P. Dubofsky
T: +1 720 566 4244
mdubofsky@cooley.com
March 30, 2018
KemPharm, Inc.
2500 Crosspark Road, Suite E126
Coralville, Iowa 52241
Re: Registration on Form S-8
Ladies and Gentlemen:
We have acted as counsel to KemPharm, Inc., a Delaware corporation (the “Company”), in connection with the filing of a registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission covering the offering of up to 586,297 shares of the Company’s Common Stock, $0.0001 par value (the “Shares”), pursuant to the Company’s 2014 Equity Incentive Plan (the “2014 Plan”).
In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related Prospectus included therein, (b) the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, (c) the 2014 Plan and (d) such other records, documents, certificates, memoranda, and other instruments as we deem necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as copies thereof, and we have assumed the due execution and delivery of all documents where due execution and delivery are prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the 2014 Plan, the Registration Statement and related Prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
We consent to the filing of this opinion as an exhibit to the Registration Statement.
Sincerely,
Cooley LLP
By: /s/ Matthew P. Dubofsky
Matthew P. Dubofsky
380 Interlocken Crescent, Suite 900, Broomfield, CO 80021-8023 T: (720) 566-4000 F: (720) 566-4099 www.cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of KemPharm, Inc. of our report dated March 30, 2018, relating to the financial statements of KemPharm, Inc., appearing in the Annual Report on Form 10-K of KemPharm, Inc. for the year ended December 31, 2017.
/s/ RSM US LLP
Orlando, Florida
March 30, 2018
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement on Form S-8 pertaining to the 2014 Equity Incentive Plan of KemPharm, Inc. of our report dated March 10, 2017 (except for the effects of the retrospective adoption of Accounting Standards Update 2016-18 discussed in Note A, Reclassifications, as to which the date is March 30, 2018), with respect to the financial statements of KemPharm, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2017, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Certified Public Accountants
Tampa, Florida
March 30, 2018